Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis

Journal of Urology

Volumn 155, Issue 4, 1996, Pages 1336-1339

  Partin, Alan W ^b   Criley, Stuart R ^b   Subong, Eric N P ^b   Zincke, Horst ^b   Walsh, Patrick C ^b   Oesterling, Joseph E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NONE

Author keywords

prostate specific antigen; prostatic neoplasms; reference values

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER INVASION; CANCER STAGING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REFERENCE VALUE;

EID: 0029968533     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66260-8     Document Type: Article

References (18)

1. Partin, A. W. and Oesterling, J. E.: The clinical usefulness of prostate specific antigen: update 1994. J. Urol., 152: 1358, 1994.
2. Collins, G. N., Lee, R. J., McKelvie, G. B., Rogers, A. C. N. and Hehir, M.: Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Brit. J. Urol., 71: 445, 1993.
3. Dalkin, B. L., Ahmann, F. R. and Kopp, J. B.: Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J. Urol., 150: 1837, 1993.
4. Crawford, E. D.: Report on the 1993 Prostate Cancer Awareness Week. Read at annual meeting of American Urological Association, San Francisco, California, May 14-19, 1994.
5. Crawford, E. D.: Personal communication.
6. Feneley, M. R., McLean, A., Webb, J. A. W. and Kirby, R. S.: Age corrected prostate specific antigen in symptomatic benign prostatic hyperplasia. J. Urol., part 2,151: 312A, abstract 337, 1994.
7. Oesterling, J. E., Kumamoto, Y., Tsukamoto, T., Girman, C. J., Guess, H. A., Masumori, N., Jacobsen, S. J. and Lieber, M. M.: Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Brit. J. Urol., 75: 347, 1995.
8. Speights, V. O., Jr., Brawn, P. N., Foster, D. M., Spiekerman, A. M., Kuhl, D. and Riggs, M. W.: Evaluation of age-specific normal ranges for prostate-specific antigen. Urology, 45: 454, 1995.
9. Berry, S. J., Coffey, D. S., Walsh, P. C. and Ewing, L. L.: The development of human benign prostatic hyperplasia with age. J. Urol., 132: 474, 1984.
10. Oesterling, J. E., Jacobsen, S. J., Chute, C. G., Guess, H. A., Girman, C. J., Panser, L. A. and Lieber, M. M.: Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. J.A.M.A., 270: 860, 1993.
11. Oesterling, J. E., Cooner, W. H., Jacobsen, S. J., Guess, H. A. and Lieber, M. M.: The influence of patient age on the serum prostate-specific antigen concentration: an important clinical observation. Urol. Clin. N. Amer., 20: 671, 1993.
12. Epstein, J. I., Walsh, P. C., CarMichael, M. and Brendler, C. B.: Pathological and clinical findings to predict tumor extent of non-palpable (stage T1C) prostate cancer. J.A.M.A., 271: 368, 1994.
13. Catalona, W. J., Hudson, M. A., Scardino, P. T., Richie, J. P., Ahmann, F. R., Flanigan, R. C., deKernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., Waters, W. B., MacFarlane, M. T. and Southwick, P. C.: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J. Urol., 152: 2037, 1994.
14. Oesterling, J. E., Jacobsen, S. J. and Cooner, W. H.: The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. J. Urol., 153: 1160, 1995.
15. Carter, H. B., Pearson, J. D., Metter, E. J., Brant, L. J., Chan, D. W., Andres, R., Fozard, J. L. and Walsh, P. C.: Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. J.A.M.A., 267: 2215, 1992.
16. Weichert-Jacobsen, K. and Loch, T.: Clinical significance of prostate specific antigen age-specific reference ranges. J. Urol., part 2, 153: 465A, abstract 945, 1995.
17. Petteway, J. and Brawer, M. K.: Age specific vs. 4.0 ng./ml. as a PSA cutoff in the screening population: impact on cancer detection. J. Urol., part 2, 153: 465A, abstract 946, 1995.
18. Pearson, J. D., Carter, H. B., Metter, E. J., Chan, D. W., Landis, P., Andres, R. and Walsh, P. C.: Sensitivity and specificity of age-specific reference ranges for PSA velocity. J. Urol., part 2, 153: 465A, abstract 947, 1995.